Xenon Pharmaceut Stock Price, News & Analysis

Xenon Pharmaceuticals (Nasdaq:XENE) reported third quarter 2020 financial results, highlighting a total revenue of $6.6 million, up from $3.5 million in Q3 2019. Cash reserves stand at approximately $191 million, extending their cash runway into 2023. The company is progressing with its XEN1101 Phase 2b and XEN496 Phase 3 clinical trials, despite COVID-19 challenges. Additionally, Patrick Machado was appointed to the Board of Directors, bringing over 20 years of biotech experience. Topline data for the X-TOLE trial is now expected in Q3 2021.

Xenon Pharmaceuticals (Nasdaq:XENE) announced it will release its Q3 2020 financial and operating results after U.S. markets close on November 5, 2020. Management will host a conference call and live webcast at 4:30 PM ET to discuss results and provide a corporate update. Investors can participate by calling (855) 779-9075 or (631) 485-4866 for international access, using conference ID 8125409. The event will be accessible on Xenon’s website and available for replay for 30 days.

Xenon Pharmaceuticals announced a positive opinion from the European Medicines Agency's COMP for orphan medicinal product designation for XEN496, aimed at treating KCNQ2 DEE. The FDA has also granted Fast Track designation for XEN496, with plans to initiate a Phase 3 clinical trial in pediatric patients by year-end. The trial will evaluate the efficacy and safety of XEN496 in approximately 40 pediatric patients. This milestone underscores the seriousness of KCNQ2-DEE and validates Xenon's precision medicine approach.

The FDA has requested additional non-clinical data from Neurocrine Biosciences to support the dose justification for NBI-921352 in a Phase II trial for pediatric SCN8A-DEE patients. This request follows the granting of Rare Pediatric Disease Designation for NBI-921352, which targets a rare pediatric epilepsy. Neurocrine and Xenon Pharmaceuticals are collaborating on this project and aim to initiate the trial in 2021, while also advancing plans for adult focal epilepsy treatment.

Xenon Pharmaceuticals (Nasdaq: XENE) announced the appointment of Dr. Chris Von Seggern as Chief Commercial Officer, effective immediately. Dr. Von Seggern will lead the company's commercial strategy for its neurology-focused therapeutics. Dr. Simon Pimstone, CEO, praised Dr. Von Seggern's extensive experience in orphan diseases and successful drug launches, signaling an exciting period for the company as it advances its epilepsy treatment pipeline. Dr. Von Seggern previously held a partner role at ClearView Healthcare Partners and brings a robust background in pharmaceuticals and strategic planning.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced that Dr. Simon Pimstone, CEO, will participate in two upcoming virtual investor conferences. The William Blair Biotech Focus Conference 2020 is scheduled for August 6, 2020, at 12:00 pm ET, focusing on new therapies for epilepsy. The Wedbush PacGrow Healthcare Conference will take place on August 11, 2020, at 3:30 pm ET. All presentations will be available for replay on Xenon's website for 30 days following the events.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced it will publish its Q2 2020 financial and operational results on August 6, 2020, post-market close. The company will host a conference call at 4:30 PM ET to discuss the results and provide a corporate update. Interested participants can join by dialing (855) 779-9075, with a replay available for 30 days following the call. Xenon focuses on developing innovative therapeutics for neurological disorders, particularly in epilepsy.

Xenon Pharmaceuticals announced that Dr. Simon Pimstone, the CEO, will present a company overview at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 2:30 pm ET. Investors can access the presentation through a webcast on the company's website, with a replay available afterward. Xenon is focused on developing innovative therapeutics for neurological disorders, particularly epilepsy, through its robust clinical-stage pipeline.

Xenon Pharmaceuticals reported steady progress in its neurology clinical programs despite COVID-19 disruptions. The company anticipates significant clinical milestones over the next year, including Phase 3 trials for XEN496 in KCNQ2 developmental and epileptic encephalopathy and top-line data from the XEN1101 trial. Financially, as of March 31, 2020, Xenon had $229.7 million in cash, with total revenue of $7.1 million for Q1 2020. The net loss for the quarter was $7.5 million, an improvement from $11.3 million in Q1 2019, reflecting operational efficiency amidst rising clinical development costs.